CMS certification 270049
Intermountain Health St Vincent Regional Hospital
1233 N 30th St, Billings, MT 59107
Intermountain Health St Vincent Regional Hospital has a CMS overall rating of 4 out of 5 stars. 76% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. Of the 27 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 5 and worse on none. Emergency patients spend a median of 2 h 38 min in its emergency department before leaving (US median 2 h 42 min).
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 976 completed surveys, 25% response rate, Oct 2024 – Sep 2025.
Emergency department
How long emergency patients spent here and how some time-critical care went, from CMS's timely and effective care measures, Oct 2024 – Sep 2025. CMS classes this emergency department's patient volume as high; busier departments tend to have longer times, so the national median for departments of the same volume is shown too. These are medians over a year of visits, not a live wait time.
| Measure | This hospital | MT | US |
|---|---|---|---|
| Median time in the emergency department before leaving Lower is better · 386 visits sampled · US median for EDs of the same volume: 3 h 22 min | 2 h 38 min | 2 h 3 min | 2 h 42 min |
| Median time for psychiatric and mental health patients Lower is better · 16 visits sampled | 2 h 30 min | 2 h 42 min | 4 h 17 min |
| Left before being seen Lower is better · 40,852 patients | 2% | 2% | 2% |
| Severe sepsis and septic shock: all recommended care given Higher is better · 363 patients | 64% | 71% | 65% |
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 2,540 cases | Too few cases | 3.3% | 3.9% |
| Heart attack 268 cases | Too few cases | 11.3% | 11.9% |
| Heart failure 352 cases | Too few cases | 10.9% | 11.1% |
| Pneumonia 447 cases | Too few cases | 14.3% | 15.2% |
| Stroke 213 cases | Too few cases | 12.8% | 11.9% |
| COPD 77 cases | Too few cases | 9.7% | 8.6% |
| Heart bypass surgery (CABG) 123 cases | Too few cases | 2.1% | 2.4% |
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Serious complications, combined measure | No different | 1.01 likely 0.73 – 1.28 | 1 |
| After hip or knee replacement 105 cases | Too few cases | 4.7% | 4.1% |
| Deaths after a serious but treatable surgical complication 146 cases | No different | 185.99 per 1,000 likely 143.28 per 1,000 – 228.71 per 1,000 | 173.3 per 1,000 |
| Pressure ulcers (bed sores) 5,063 cases | No different | 0.13 per 1,000 likely 0 per 1,000 – 0.74 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 6,094 cases | No different | 0.15 per 1,000 likely 0 per 1,000 – 0.35 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 6,278 cases | No different | 0.28 per 1,000 likely 0.09 per 1,000 – 0.47 per 1,000 | 0.27 per 1,000 |
| Bleeding or hematoma after surgery 2,237 cases | No different | 2.64 per 1,000 likely 1.28 per 1,000 – 3.99 per 1,000 | 2.34 per 1,000 |
| Kidney injury needing dialysis after surgery 1,173 cases | No different | 2.06 per 1,000 likely 0.65 per 1,000 – 3.46 per 1,000 | 1.67 per 1,000 |
| Breathing failure after surgery 1,152 cases | No different | 14.14 per 1,000 likely 8.97 per 1,000 – 19.31 per 1,000 | 9.42 per 1,000 |
| Blood clots in the lungs or legs after surgery 2,436 cases | No different | 3.06 per 1,000 likely 1.26 per 1,000 – 4.86 per 1,000 | 3.52 per 1,000 |
| Sepsis after surgery 1,154 cases | No different | 6.59 per 1,000 likely 3.36 per 1,000 – 9.82 per 1,000 | 5.27 per 1,000 |
| Surgical wound splitting open 502 cases | No different | 1.84 per 1,000 likely 0.41 per 1,000 – 3.28 per 1,000 | 1.77 per 1,000 |
| Accidental cut or tear during abdominal surgery 1,245 cases | No different | 0.76 per 1,000 likely 0 per 1,000 – 1.69 per 1,000 | 1.06 per 1,000 |
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Bloodstream infections from central lines (CLABSI) | No different | 1.84 likely 0.97 – 3.19 | 1 |
| Urinary tract infections from catheters (CAUTI) | Better | 0.34 likely 0.09 – 0.92 | 1 |
| Surgical site infections after colon surgery | Worse | 2.08 likely 1.02 – 3.82 | 1 |
| Surgical site infections after abdominal hysterectomy | No different | 1.22 likely 0.21 – 4.04 | 1 |
| MRSA bloodstream infections | No different | 0.23 likely 0.01 – 1.14 | 1 |
| C. diff intestinal infections | Better | 0.35 likely 0.17 – 0.64 | 1 |
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Readmitted after a heart attack 269 cases | Too few cases | 12.5% | 14.4% |
| Readmitted after heart failure 390 cases | Too few cases | 18.7% | 21.3% |
| Readmitted after pneumonia 556 cases | Too few cases | 16.4% | 17.3% |
| Readmitted after COPD 115 cases | Too few cases | 19.4% | 20% |
| Readmitted after heart bypass surgery 108 cases | Too few cases | 9.3% | 11% |
| Readmitted after hip or knee replacement 112 cases | Too few cases | 5.7% | 5.8% |
| Days back in hospital after a heart attack 281 cases | Too few cases | -6.3 days per 100 | — |
| Days back in hospital after heart failure 386 cases | Too few cases | -25.4 days per 100 | — |
| Days back in hospital after pneumonia 467 cases | Too few cases | -15.8 days per 100 | — |
| Unplanned visits after an outpatient colonoscopy 2,164 cases | No different | 12 per 1,000 likely 9.3 per 1,000 – 15.2 per 1,000 | 13 per 1,000 |
| Hospital admissions during outpatient chemotherapy 245 cases | No different | 11.9 per 100 likely 9.1 per 100 – 15.1 per 100 | 10.7 per 100 |
| ER visits during outpatient chemotherapy 245 cases | No different | 5 per 100 likely 3.5 per 100 – 7.1 per 100 | 5.4 per 100 |
| Unplanned visits after outpatient surgery 838 cases | No different | 1.1 likely 0.9 – 1.4 | — |
1 more measure had too few cases here to report.
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $597,023
- 2020 $1.1M
- 2021 $1.2M
- 2022 $2.9M
- 2023 $2.1M
- 2024 $1.9M
- 2025 $1.5M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Medical devices and supplies on long-term loan | $30,000 | 1 |
| Space rental and facility fees | $2,050 | 4 |
| Speaking, teaching and other services | $650 | 2 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Abbvie INC. | $280,695 | 18 |
| Exelixis Inc. | $263,133 | 15 |
| Merck Sharp & Dohme LLC | $247,347 | 16 |
| AstraZeneca Pharmaceuticals LP | $199,970 | 5 |
| Pfizer INC. | $72,421 | 12 |
| Eli Lilly and Company | $62,132 | 5 |
| Genentech, Inc. | $60,144 | 19 |
| Aveo Pharmaceuticals, Inc. | $55,084 | 40 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer Exelixis Inc. | $263,133 |
| A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Mo… AstraZeneca Pharmaceuticals LP | $86,939 |
| A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Plac… Merck Sharp & Dohme LLC | $77,754 |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease… ABBVIE INC. · NCT05409066 | $72,711 |
| a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with pl… AstraZeneca Pharmaceuticals LP | $72,326 |
| A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Sub… ABBVIE INC. · NCT05578976 | $64,744 |
| AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PART… PFIZER INC. | $55,977 |
| TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherap… Aveo Pharmaceuticals, Inc. · NCT04987203 | $55,084 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Intermountain Health St Vincent Regional Hospital
Is Intermountain Health St Vincent Regional Hospital a good hospital?
Intermountain Health St Vincent Regional Hospital has a CMS overall rating of 4 out of 5 stars. Of the 27 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 5 and worse on none. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend Intermountain Health St Vincent Regional Hospital?
76% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 976 completed HCAHPS surveys.
How long is the wait in the Intermountain Health St Vincent Regional Hospital emergency room?
Emergency patients spend a median of 2 h 38 min in its emergency department before leaving (US median 2 h 42 min). Among US emergency departments with high patient volume, like this one, the median is 3 h 22 min. 2% of emergency patients left before being seen (US 2%). These are medians over a year of visits, not a live wait time.
Does Intermountain Health St Vincent Regional Hospital receive money from drug and device companies?
Drug and device makers reported $1.5M in payments to Intermountain Health St Vincent Regional Hospital for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.